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What We’ll Cover 
1. Breast Cancer 
2. Colon Cancer 
3. Lung Cancer 
4. Prostate Cancer 
Breast Cancer 
2014 
Estimated new cases    232,670 
Estimated deaths     40,000 
©2013 American Cancer Society, Inc. No.0059.55 
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The Mammography Debate –  
Understanding the Science, Positions, and Beliefs  
• Positions of scientists, journals, and 
reporters are largely entrenched  
• The randomized trial data are flawed 
and are old 
• The ACA was a game changer 
– Linking USPSTF guidelines to coverage 
 
USPSTF 2009 Guideline Change 
 The USPSTF downgraded their 
recommendation for mammography 
screening in women aged 40-49 years 
from a B to a C 
 
 A “C” recommendation indicates that 
harms and benefits are about equal 
 
“The USPSTF recommends against routine 
screening mammography in women 
aged 40 to 49 years.” 
 
 
 
Ann Intern Med; 151:716-726 W236 
 
They Continued: 
“  …the decision to start regular, biennial 
screening mammography before the age 
of 50 years should be an individual one 
and take into account patient context, 
including the patient’s values regarding 
specific benefits and harms.” 
The USPSTF performed an updated meta-
analysis and found: 
• 15% mortality reduction among 
women screened in their 40’s 
• 14% mortality reduction for women 
screened in their 50’s 
 
Nelson HD, Fu R, et al. Ann Intern Med 2009; 151:703-715 W226-W235 
 
Number Needed To Be Invited To 
Screening To Save One Life 
Ultimately, the USPSTF concluded that the 
majority of screening benefit was due to 
screening women aged 50-74 years.  
Screening at 40 only contributes to an 
additional 3% of mortality reduction 
 
The Evolving Evidence for Breast 
Cancer Screening—Benefits & Harms 
The argument against screening 
women in their 40s 
• Risk of developing and dying from breast 
cancer during the decade of the 40s is low 
 
• While the relative risk of dying from breast 
cancer associated with screening in women 
ages 40-49 is similar to women ages 50-59, the 
absolute benefit is lower 
 
The argument against screening 
women in their 40s 
• The risk of harms (false positives, etc.) is 
high 
 
• Thus, the balance of benefits and harms 
indicates a recommendation against 
routine screening (C rating) 
 
Premature mortality and incidence based mortality 
from breast cancer, U.S Women 
• Percent of deaths from 
breast cancer by age at 
diagnosis, U.S., 2005-2006 
– < 40 7.7% 
– 40-49 17.8% 
– 50-59 22.3% 
– 60-69 19.0% 
– 70-79 18.8% 
– 80+ 14.5% 
Source: SEER Cancer Statistics Review,1975-2006. 
Meta-analysis of the RCTs, Women age 39-49 
RR - log scale 
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0.85 (0.73, 0.98) 
0.65 (0.40, 1.05) 
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 1.52 (0.80, 2.88) 
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Combined 
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 2-county 
 Malmo 
 HIP 
15% reduction in breast cancer mortality 
20% reduction without NBSS-1  
Hetero, p=0.30 
I2=17% 
Evaluation of Service Screening in Sweden 
Effectiveness of Population-Based Service Screening 
With Mammography for Women Ages 40 to 49 Years 
 
• Contemporaneous 
comparison of breast 
cancer mortality in 
Swedish counties offering 
mammography vs. those 
not offering 
mammography 
• 1986-2005 
• Average follow-up = 16 
years 
Cancer 2010; published online: 29 SEP 2010  
Swedish Mammography In Young Women 
Cohort 
• Screened every 18 to 24 months 
 
• All outcomes in Sweden are recorded in the 
Swedish County Registry  
 
• Analyzed data both based on invitation and 
attendance 
Helquist BN et.al. Cancer 2010 1 
 
 
Swedish Results: Before Screening –  
1970-1985 
  
 
 
 
 
RR: 0.94 (CI 0.85-1.05) 
No Reduction In Mortality  
Breast Cancer 
Deaths 
Person-Years 
Study Group 607 4.8 million 
Control Group 846 6.3 million  
Swedish Results: Study Period – 
1986-2005 
 
 
 
 
RR 0.71 (CI 0.62-0.80) 
29% Reduction In Mortality 
 
Number needed to screen to save 1 life: 1252 
Breast Cancer 
Deaths 
Person-Years 
Study Group 803 7.3 million 
Control Group 1238 8.8 million 
Map of Study and Control Group Areas, and Crude Cumulative 
Breast Cancer Mortality  per 100,000 Person Years 
Cancer 2010; published online: 29 SEP 2010  
RR = 0.74; 95% CI 0.66 – 0.83)  
Control Group 
Study Group 
Results from randomized trials are a solid 
basis for breast cancer screening policy 
• Mortality reductions in the trials, closely 
parallel the reduction in the risk of being 
diagnosed with an advanced breast cancer. 
 
• Those trials that succeeded in downstaging, 
also succeeded in reducing breast cancer 
deaths. 
• Two important points: 
– Long term follow-up is necessary to measure the full 
benefit of breast cancer screening 
– With long follow-up, the number-needed-to-screen to save 
one life steadily improves 
Radiology June 28, 2011 110469  
31% fewer deaths 
After 29 years 
Number Needed to Screen (NNS) vs. Number Needed 
to Invite (NNI) to Avoid One Breast Cancer Death 
Age Group Swedish data (NNS)1 USPSTF 
(NNI)2 
Overall 464 1224 
40-49 726 1,904 
50-59 260 1,339 
60-69 198 377 
1 Number Needed to Screen (NNS) Every 2 Years (40-49—18 mos.) for a Period of Ten Years, with 20 
Years of Follow-up, to Save One Life. 
2 Number Needed to Invite (NNI), estimated from randomized trial data with variable screening intervals, 
variable screening rounds, different rates of adherence and non-compliance, and variable periods of 
follow-up (14 yrs.) 
Adjusted absolute risk estimates of the number needed 
to screen to save one life  based on UK Review Standard* 
Source No. needed to 
screen/invite(ori
ginal)* 
No. needed to screen 
(adjusted) 
UK review (2012) 180 180 
USPSTF, depending on age 
(2009) 
377-1904 193 
Nordic Cochrane Review (2011) 2000† 257 
EUROSCREEN (2012) 90 64-96 
* Original estimates are adjusted to the same scenario used in the UK Independent Review, 
i.e., the impact of screening UK women ages 50-51 every 3 years for 20 years on mortality in 
women ages 55-79.  
Adverse Effects and Harms 
• False positive findings 
• Anxiety 
• Overdiagnosis 
False Positive and Patient Recall in 
Mammography Screening 
The USPTF labeled all women with an 
initial abnormal mammogram who were 
found to not have cancer as “false 
positives” – 100 out of 1000 women 
screened  
False Positives and Patient Recall- 
An Analysis of the 100 Recalls 
• 56 out of 100 will have additional views 
and a mammogram and will be found to 
be normal 
 
• 25 out of 100 will have a 6 month follow-
up 
 
False Positives and Patient Recall- 
An Analysis of the 100 Recalls 
• 19 (1.9% of the 1000) will have a biopsy 
• 6 of 19 (32%) will have cancer. An excellent 
yield 
• Biopsies of a palpable lump: only 15% have 
cancer  
©2013 American Cancer Society, Inc. No.0059.55 
Schwartz & Colleagues found: 
– Women had high awareness of false positives 
from mammography 
 
– Women were highly tolerant of false positives 
• 63% felt 500 FP per life saved was 
reasonable 
• 37% felt 10,000 FP per life saved was 
reasonable 
Schwartz & Colleagues found: 
– Women who had had experienced a FP 
result had the same level of tolerance as 
women who had not had experienced a FP 
 
– 63% did not regard false positives as an 
important factor in decisions about 
screening 
Over Diagnosis:  
The Hottest Topic In Cancer Screening 
Lack of consistent definition 
and methods of measurement 
causes confusion. 
Over Diagnosis Definitions 
• Three potential definitions:  
• A cancer with no biologic potential to cause 
harm 
• A cancer that is very unlikely to cause harm 
within the predicted life expectancy of the 
individual 
• Any cancer case where the individual dies 
before the cancer causes harm 
 
 
 
• Excess number of cancers detected in the screening 
arm compared to the control arm 
• Effective screening should detect more cancers earlier 
than no screening 
• Cancers detected through usual care should catch-up 
with time 
• If there is over-diagnosis the usual care group will 
never catch up   
Measuring Over Diagnosis 
Measuring Over-Diagnosis 
• The natural history of cancers may be 
longer than we suspected 
 
• Usual care group may take many years to 
catch up 
Measuring Over-Diagnosis 
• Some usual care patients, who would have 
developed the target cancer,  will die of 
another cause before the cancer is diagnosed 
• 15 to 20 years of measurement are needed to 
accurately measure over-diagnosis 
• In the meantime, some women in usual care 
will get screened which may falsely lower the 
estimate of over diagnosis 
 
Overdiagnosis 
 
• Estimates of overdiagnosis of screen detected 
breast tumors range from 0 -  > 50%, with 
some claiming that it is the major harm of 
screening 
 
• Reality: To estimate overdiagnosis, we must 
examine incidence rates over time, and adjust 
for: 
– Pre-existing trend of increasing incidence 
– Lead time 
 
  
 
 
 
Overdiagnosis Estimates Based on Adjustment for 
Incidence Trends and Lead-time 
%
 O
ve
rd
ia
gn
o
se
d
 
Puliti, et al. JMS 2012;19(1) 
Adjusted Estimates Not Adequately Adjusted Estimates 
Are there harms from not screening? 
• A study of 1977 women aged 40-49 diagnosed 
with breast cancer compared the tumor 
characteristics, treatment regimens used, and 
long-term outcome of women with symptomatic 
versus women with mammographically detected 
breast cancer.  
 
Radiology 2012;262:797-806.) 
Are there harms from not screening? 
• Women with symptomatically detected breast 
cancer had: 
– A higher rate of mastectomy (47% vs. 25%) 
– Larger average tumor size (3.02 vs. 1.63 cm) 
– Significantly worse disease survival 
 
 
Radiology 2012;262:797-806.) 
Is there a role for ultrasound screening in 
women with significant breast density? 
• 2809 women with 
heterogeneously dense 
breasts in at least one 
quadrant were recruited to 
undergo both 
mammography and 
ultrasound, with the exams 
delivered in a randomized 
order 
Performance of Screening With Combined Mammography 
and Ultrasound vs. Mammography or Ultrasound Alone 
Berg W, et al. JAMA 2008;299:18 
Sensitivity  
Mammography plus Ultrasound 77.5% 
Mammography alone 50% 
Screening with mammography and ultrasound improves the 
detection of cancer, but at significant increase in false 
positives 
• The positive predictive value of biopsy 
recommendation after full diagnostic 
workup was: 
• Mammography: 22.6% (95% CI, 14.2%-
33%) 
• Ultrasound: 8.9% (95% CI, 5.6%-13.3%) 
• Combination: 11.2% (95% CI. 7.8%-15.6%) 
 
 
Berg W, et al. JAMA 2008;299:18 
Breast Cancer Screening Guidelines:  
More Agreement Than Disagreement 
Every Guideline Recommends That 
• All women 50 and older should have a 
mammogram every 1 to 2 years, until life 
expectancy becomes limited 
• All women ages 40-49 should be offered a 
mammogram with or without shared decision 
making 
• Corollary: Accepting a refusal without 
discussion is NOT recommended 
 
Best Estimates of Over-Diagnosis of 
Breast Cancer  
• 1-3% for invasive cancer 
 
• 15-25% for DCIS 
– Ductal Carcinoma In Situ is a pre-cancerous 
condition that is currently treated just like 
cancer 
 
Reducing Over Diagnosis of Breast Cancer 
and Particularly DCIS 
–New approaches to genetic 
profiling and to treatment options 
hold potential to reduce 
overtreatment 
And for those who argue that the impact is 
not big enough or fast enough…….one 
more example 
Cancer Mortality Rates in Denmark, by 
Major Cancer, Women 
Colon Cancer 
2014 
Estimated new cases    136,830 
Estimated deaths     50,310 
Colon Cancer Screening:  A Public Health 
Success Story 
• Colon cancer mortality has dropped over 
40% from its peak  
• Colon cancer incidence dropped 30% 
between 2000 and 2010 
• Colon cancer incidence is rising in 
younger people and in other countries 
 Trends in Colorectal Cancer Incidence Trends* by 
Age and Sex, 2001-2010 
*Rates are age adjusted to the 2000 US standard population. 
Source: North American Association of Central Cancer Registries CiNA Analytic File, 1995-2010. 
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API indicates Asian/Pacific Islander. Trends for American Indian/Alaska Natives are not shown due to sparse data. Rates are per 100,000 and age 
adjusted to the 2000 US standard population. *Rates are two-year moving averages. †Rates are three-year moving averages. ‡Persons of Hispanic 
origin may be of any race; rates exclude deaths from CT, DC, LA, ME, MD, MN, MS, NH, NY, ND, OK, SC, VT, and VA due to incomplete ethnicity 
data.  
Source: National Center for Health Statistics, Centers for Disease Control and Prevention, as provided by the Surveillance, Epidemiology, and End 
Results Program, National Cancer Institute. 
Trends in Colorectal Cancer Mortality Rates by Sex 
and Race/Ethnicity, US, 1975-2010 
Males Females 
Colorectal Cancer Incidence 
Sedentary life-
styles, increase in 
red meat 
consumption and 
obesity increase risk 
for colorectal cancer 
Increasing Decline in Colorectal Cancer Death Rates, 1970-2010 
Decline per decade: 3% 25% 15% 11% 
Seven Basic Truths of Colon Cancer 
Screening 
1. If you only offer colonoscopy you can 
achieve very good but not spectacular 
screening rates 
Stool Blood Testing – A Critical Part of 
ANY CRC Screening Strategy 
 
• Even if you recommend colonoscopy for 
all, some people won’t get one or can’t 
get one.  Using colonoscopy exclusively 
will, inevitably, lead to a screening gap 
Evaluating Test Strategies for 
Colorectal Cancer Screening 
  
 Zauber and her team conducted a 
decision analysis using microsimulation 
models 
 
 
Zauber AG et.al. Ann of Int Med. 2008, 149; 659-669 
• Number of life-years gained is essentially 
identical regardless of screening strategy 
used: 
– Sensitive guaiac FOBT annually 
– Fecal Immunochemical Test (FIT) annually 
– Flexible sigmoidoscopy every 5 years with 
mid-interval sensitive FOBT 
– Colonoscopy every 10 years 
ASSUMING 100% ADHERENCE 
Fecal Immunochemical Tests (FIT’s) 
Should Replace Guaiac FOBT 
• FIT’s 
– Demonstrate superior sensitivity and specificity 
– Are specific for colon blood and are unaffected by 
diet or medications 
– Some can be developed by automated readers 
– Some improve patient participation in screening 
 
 
Allison JE, et.al. J Natl Cancer Inst. 2007; 191:1-9 
Cole SR, et.al. J Med Screen. 2003; 10:117-122 
FIT’s available in the US 
Name Manufacturer 
InSure Enterix,  Quest Company 
Hemoccult-ICT Breckman-Coulter 
Instant-View Alpha Scientific Designs 
MonoHaem Chemicon International 
Clearview Ultra-FOB Wampole Laboratory 
Fit-Chek Polymedco 
Hemosure One Step WHPM, Inc. 
Magstream Hem Sp Fujirebio, Inc. 
Many Patients Prefer FOBT 
• Diverse sample of 323 adults given 
detailed side-by-side description of FOBT 
and colonoscopy (DeBourcy et al. 2007) 
– 53% preferred FOBT 
– Almost half felt very strongly about their 
preference 
Many Patients Prefer FOBT 
• 212 patients at 4 health centers rated different 
screening options with different attributes 
– 37% preferred colonoscopy 
– 31% preferred FOBT 
• Nationally representative sample of 2068 VA 
patients given brief descriptions of each 
screening mode (Powell et al. 2009) 
– 37% preferred colonoscopy 
– 29% preferred FOBT 
 
 (Hawley et al. 2008) 
Many Patients Prefer FOBT 
Randomized clinical trial in which 997 
patients in the San Francisco PH care 
system received different 
recommendations for screening 
 
– Colonoscopy recommended:  38% completed screening 
– FOBT recommended:    67% completed screening 
– Colonoscopy or FOBT:   69% completed screening 
Many patients may forgo screening if they are 
not offered an alternative to colonoscopy 
(Inadomi et al. 2012) 
Seven Basic Truths of Colon Cancer 
Screening 
2. If you only offer screening to patients 
who are coming to a primary care 
office, you can achieve very good but 
not spectacular screening rates 
Population Management is Vital 
• Every practice must have a system to 
assess screening gaps and conduct 
population outreach by letter or by 
phone 
Seven Basic Truths of Colon Cancer 
Screening 
3. If you give out FIT or FOBT tests but do 
not track whether the patient returns 
the test and prompt them to do so, 
return rates will be poor 
Seven Basic Truths of Colon Cancer 
Screening 
4. If you ask a patient to schedule their 
colonoscopy but do not schedule it 
before they leave the office, only about 
one half of them will call and schedule 
Seven Basic Truths of Colon Cancer 
Screening 
5. If you are “screening” patients with a 
stool blood test at the time of a rectal 
exam, it’s time to stop.  This method 
doesn’t work. 
Seven Basic Truths of Colon Cancer 
Screening 
6. The quality of colonoscopy varies 
dramatically … and this has a major 
impact on outcomes 
Interval Cancer: Why? 
• New, fast growing lesions 
• Incomplete removal (19-27%) 
• Missed lesions 
– Up to 17% of polyps > 1cm are missed! 
– Less protection in proximal colon 
©2013 American Cancer Society, Inc. No.0059.55 
Seven Basic Truths of Colon Cancer 
Screening 
7. Surveillance guidelines are not being 
followed, leading to some over-testing 
and some under-testing 
Recommendations for Adenoma 
Surveillance  
Category Next examination 
1-2 tubular adenomas < 10 mm 5-10 years 
> 3 tubular adenomas < 10 mm 3 years 
> 10 adenomas  < 3 years 
Any adenoma with villous features 3 years 
Any adenoma with high grade dysplasia 3 years 
Sessile adenoma with piecemeal excision 2-6 months 
Lieberman DA, et al. Gastroenterology 2012;143:844–857 
©2013 American Cancer Society, Inc. No.0059.55 
Recommendations for Adenoma Surveillance 
After First Surveillance Colonoscopy 
Baseline  
Colonoscopy 
First  
Surveillance 
Interval for 2nd 
Surveillance (y) 
Low risk adenoma (LRA) HRA 
LRA 
No adenoma 
3 
5 
10 
High risk adenoma (HRA) HRA 
LRA 
No adenoma 
3 
5 
5 
Lieberman DA, et al. Gastroenterology 2012;143:844–857 
©2013 American Cancer Society, Inc. No.0059.55 
Surveillance Recommendations Serrated 
Polyps 
 
Category Surveillance interval 
Hyperplastic polyp No surveillance, unless multiple, large and proximally 
located 
Sessile serrated adenoma/polyp (SSA/P) 
 without cytological dysplasia  
q5 years if < 3 lesions, all <1 cm size;  
q3 years if ≥ 3 lesions, or any ≥1 cm size 
SSA/P with cytological dysplasia 
 
 
Traditional serrated adenoma (TSA) 
q3 years, after ensuring complete resection 
 
Same as SSPD 
 
Suspected Type I hyperplastic polyposis (serrated 
adenomatous polyposis) 
 
q1-3 years, with resection of polyps >5 mm vs. surgery 
84 Rex et al. Am J Gastroenterol 2012;107:1315-1329  
 Screening Older Patients 
Screening Frail Elderly Patients for 
Colorectal Cancer 
• American Geriatrics Society recommends 
individualized health screening decisions for older 
patients 
 
• US Preventive Services Task Force recommends that 
the decision to screen people 76-85 years old should 
be individualized (not routine), and discouraged in 
those > 85 years old 
Screening Frail Elderly Patients for 
Colorectal Cancer 
• ACS does not currently address CRC screening in the 
elderly, but they will likely recommend 
individualized decision-making in the future, as they 
do with their breast and prostate cancer screening 
guidelines 
©2013 American Cancer Society, Inc. No.0059.55 
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Adapted from Warren JL et al. Ann Int  Med 2009;150:849-57. 
Age-Related Risk of Colonoscopy 
An Opportunity to Substantially Eliminate Colon 
Cancer as a Major Public Health Problem 
• Over 80 organizations from all sectors of 
public life have signed a pledge to 
achieve the goal of having 80% of all 
eligible adults up to date with CRC 
screening by the end of 2018 
We have A Symbol  
We Have A Month  
 
 
 
 
 
 
(…March) 
We Have A Plan 
Time for Coordinated PUSH 
80% Colon Cancer 
Screening Rate By 2018 
 
……I Can See It!!! 
 
Lung Cancer 
2014 
 
Estimated New Cases    224,210 
Estimated deaths     159,260 
©2013 American Cancer Society, Inc. No.0059.55 
©2013 American Cancer Society, Inc. No.0059.55 
National Lung Screening Trial 
 53,000 current or ex-smokers (≥ 30 
pack-year) ages 55-74 
Randomly Assigned 
Low dose helical (spiral) CT Chest X-Ray 
NLST – Preliminary Results 
 20% fewer lung cancer deaths in spiral 
CT group 
 
 Results were highly statistically 
significant 
…. And That’s Not All 
 
 7% reduction in all cause 
mortality in CT group! 
A 20% reduction in lung cancer 
death rate would prevent 30,000 
lung cancer deaths  every year! 
©2013 American Cancer Society, Inc. No.0059.55 
 That’s equivalent to wiping out all deaths 
from prostate cancer in men, or … 
©2013 American Cancer Society, Inc. No.0059.55 
 …all deaths from cervix cancer, uterine cancer, and 
ovarian cancer in women… …combined 
Major Complication Associated With Invasive Diagnostic 
Procedure Following Positive Low-Dose CT Screen 
Category 
% with major 
complications 
Did not result in cancer 
diagnosis 
0.06 
Did result in cancer diagnosis 11.2 
 16 participants in low-dose CT group (10 
of whom had lung cancer) and 10 in the 
radiography group (all of whom had lung 
cancer) died within 60 days after an 
invasive diagnostic procedure 
The ACS Guideline 
“Clinicians with access to high volume, 
high quality lung cancer screening and 
treatment centers should initiate a 
discussion about screening with 
apparently healthy patients aged 55 to 74 
years who have at least a    30 pack/year 
smoking history and who currently smoke 
or have just quit within the past 15 years.” 
“A process of informed and shared 
decision making … should occur 
before any decision is made to initiate 
lung cancer screening.” 
“Smoking cessation counseling 
remains a high priority for clinical 
attention in current smokers.” 
“Where risk seems to approximate or 
exceed the NLST eligibility criteria in 
one category but not another, 
clinicians should consider offering the 
chance to screen.” 
Coverage for Low Dose C-T Screening 
is a Reality 
• USPSTF B recommendation requires 
coverage by most commercial plans 
 
• CMS currently considering coverage 
Prostate cancer 
2014 
 
Estimated new cases    233,000 
Estimated deaths     29,480 
Some Prostate Cancer Facts 
From 2006-2010: 
– The median age at diagnosis was 66 y.o. 
– 0.6% diagnosed between 35-44 
– 9.6% between 45-54 
– 32.3% between 55-64 
– 35.8% between 65-74 
– 17.7% between 75-84 
 
Some Prostate Cancer Facts 
From 2006-2010: 
– The median age at death for Prostate 
Cancer:  80 y.o. 
– 1.6% between 45-54 
– 8.3% between 55-64 
– 20% between 65-74 
– 37.6% between 75-84 
     
 
Survival for men diagnosed with 
distant disease is not great:  27.9% 
at 5 years 
Prostate Cancer Screening and Co-
Morbidities 
The PLCO study showed no benefit from 
inviting men to be screened for prostate 
cancer. 
Analysis of PLCO stratified by co-morbidities 
may guide targeted screening 
In 10 years f/u of PLCO, 9,565 deaths 
occurred, 164 from prostate cancer 
 
60% of these patients had minimal or no      
co-morbidity 
Prostate Cancer Deaths in PLCO Men 
With No or Minimal Co-Morbidity 
 
Intervention group:  22 
Control group:  38 
 
RR:  0.56 (p = 0.03) 
 
Crawford, et.al.  J of Clin Onc Vol 29(4): 355-361 
©2013 American Cancer Society, Inc. No.0059.55 
Active Surveillance in Prostate Cancer 
Treatment 
Recurrence risk and 
expected years to live Active Surveillance 
Very low risk  
Low risk >10 years 
• PSA every 3 months 
• DRE every 6 months 
• Prostate biopsy at least every 
12 months 
Low risk with <10 
years 
Intermediate risk with 
<10 years 
• PSA every 6 months 
• DRE every 6 months 
NCCN Guidelines – Prostate Cancer www.nccn.org  
When To Begin Treatment 
• Rising Gleason score 
• Increasing cancer volume on biopsies 
• Doubling of PSA in <3 years 
Prostate Cancer Take Home Points 
1. Abandoning PSA screening will lead to 
an increase in stage of diagnosis and 
more prostate cancer deaths 
 
2. More men die from prostate cancer 
than from colon cancer but the median 
age of death is 6 years older 
 “A man who chooses to be screened might 
place a higher value on avoiding death from 
prostate cancer, and might be willing to risk 
injury to urinary, sexual or bowel function.” 
 “A man who chooses not to be screened 
might place a higher value on avoiding the 
potential harms of screening and 
treatment, such as anxiety or the risk of 
injury to urinary, sexual or bowel function, 
and might be willing to accept a higher risk 
of dying from prostate cancer prematurely.” 
The Department of Family and 
Community Medicine  - 40 years 
of excellence in education , 
research, clinical care……..and 
cancer screening 

